Systemic human CD34+ cells populate the brain and activate host mechanisms to counteract nigrostriatal degeneration

Mando J. Corenblum; Andrew J. Flores; Michael Badowski; David T. Harris; Lalitha Madhavan

doi:10.2217/rme.15.32

Systemic human CD34⁺ cells populate the brain and activate host mechanisms to counteract nigrostriatal degeneration

Mando J. Corenblum, Andrew J. Flores, Michael Badowski, David T. Harris, Lalitha Madhavan

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Aim: Here we investigated the neuroprotective potential of systemic CD34⁺ human cord blood cells (hCBCs) in a 6-hydroxydopamine rat model of Parkinson's disease. Methods: Purified CD34⁺ hCBCs were intravenously administered to rats subjected to 6-hydroxydopamine 24 h earlier, and behavioral and immunohistological analysis performed. Results: CD34⁺ hCBC administration significantly prevented host nigrostriatal degeneration inducing behavioral recovery in treated rats. Although donor hCBCs did not differentiate into neural phenotypes, they stimulated the production of new neuroblasts and angiogenesis, and reduced gliosis in recipient animals. Importantly, surviving donor hCBCs were identified, and their tissue distribution pattern correlated with the observed therapeutic effects. Conclusion: Peripherally applied CD34⁺ hCBCs can migrate into brain tissues and elicit host-based protective mechanisms to support the survival of midbrain dopamine neurons.

Original language	English (US)
Pages (from-to)	563-577
Number of pages	15
Journal	Regenerative Medicine
Volume	10
Issue number	5
DOIs	https://doi.org/10.2217/rme.15.32
State	Published - Aug 1 2015

Keywords

6-OHDA
CD34 mononuclear cells
Parkinson's disease
angiogenesis
cord blood
neurogenesis
neuroprotection

ASJC Scopus subject areas

Biomedical Engineering
Embryology

Access to Document

10.2217/rme.15.32

Cite this

@article{3f9da71918604fa6a365591643d625b3,

title = "Systemic human CD34+ cells populate the brain and activate host mechanisms to counteract nigrostriatal degeneration",

abstract = "Aim: Here we investigated the neuroprotective potential of systemic CD34+ human cord blood cells (hCBCs) in a 6-hydroxydopamine rat model of Parkinson's disease. Methods: Purified CD34+ hCBCs were intravenously administered to rats subjected to 6-hydroxydopamine 24 h earlier, and behavioral and immunohistological analysis performed. Results: CD34+ hCBC administration significantly prevented host nigrostriatal degeneration inducing behavioral recovery in treated rats. Although donor hCBCs did not differentiate into neural phenotypes, they stimulated the production of new neuroblasts and angiogenesis, and reduced gliosis in recipient animals. Importantly, surviving donor hCBCs were identified, and their tissue distribution pattern correlated with the observed therapeutic effects. Conclusion: Peripherally applied CD34+ hCBCs can migrate into brain tissues and elicit host-based protective mechanisms to support the survival of midbrain dopamine neurons.",

keywords = "6-OHDA, CD34 mononuclear cells, Parkinson's disease, angiogenesis, cord blood, neurogenesis, neuroprotection",

author = "Corenblum, {Mando J.} and Flores, {Andrew J.} and Michael Badowski and Harris, {David T.} and Lalitha Madhavan",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2015",

month = aug,

day = "1",

doi = "10.2217/rme.15.32",

language = "English (US)",

volume = "10",

pages = "563--577",

journal = "Regenerative Medicine",

issn = "1746-0751",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Systemic human CD34+ cells populate the brain and activate host mechanisms to counteract nigrostriatal degeneration

AU - Corenblum, Mando J.

AU - Flores, Andrew J.

AU - Badowski, Michael

AU - Harris, David T.

AU - Madhavan, Lalitha

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Aim: Here we investigated the neuroprotective potential of systemic CD34+ human cord blood cells (hCBCs) in a 6-hydroxydopamine rat model of Parkinson's disease. Methods: Purified CD34+ hCBCs were intravenously administered to rats subjected to 6-hydroxydopamine 24 h earlier, and behavioral and immunohistological analysis performed. Results: CD34+ hCBC administration significantly prevented host nigrostriatal degeneration inducing behavioral recovery in treated rats. Although donor hCBCs did not differentiate into neural phenotypes, they stimulated the production of new neuroblasts and angiogenesis, and reduced gliosis in recipient animals. Importantly, surviving donor hCBCs were identified, and their tissue distribution pattern correlated with the observed therapeutic effects. Conclusion: Peripherally applied CD34+ hCBCs can migrate into brain tissues and elicit host-based protective mechanisms to support the survival of midbrain dopamine neurons.

AB - Aim: Here we investigated the neuroprotective potential of systemic CD34+ human cord blood cells (hCBCs) in a 6-hydroxydopamine rat model of Parkinson's disease. Methods: Purified CD34+ hCBCs were intravenously administered to rats subjected to 6-hydroxydopamine 24 h earlier, and behavioral and immunohistological analysis performed. Results: CD34+ hCBC administration significantly prevented host nigrostriatal degeneration inducing behavioral recovery in treated rats. Although donor hCBCs did not differentiate into neural phenotypes, they stimulated the production of new neuroblasts and angiogenesis, and reduced gliosis in recipient animals. Importantly, surviving donor hCBCs were identified, and their tissue distribution pattern correlated with the observed therapeutic effects. Conclusion: Peripherally applied CD34+ hCBCs can migrate into brain tissues and elicit host-based protective mechanisms to support the survival of midbrain dopamine neurons.

KW - 6-OHDA

KW - CD34 mononuclear cells

KW - Parkinson's disease

KW - angiogenesis

KW - cord blood

KW - neurogenesis

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=84938574030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938574030&partnerID=8YFLogxK

U2 - 10.2217/rme.15.32

DO - 10.2217/rme.15.32

M3 - Article

C2 - 26237701

AN - SCOPUS:84938574030

SN - 1746-0751

VL - 10

SP - 563

EP - 577

JO - Regenerative Medicine

JF - Regenerative Medicine

IS - 5

ER -